Clinical trial NCT04864717 - References

Cancer, Treatment-Related — Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Citation(s)

•   Agnew T, Furber G, Leach M, Segal L
  A Comprehensive Critique and Review of Published Measures of Acne Severity. J Clin Aesthet Dermatol. 2016 Jul;9(7):40-52. Epub 2016 Jul 1. Review.
•   Andrews ED, Garg N, Patel AB
  A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions. J Am Acad Dermatol. 2020 Apr;82(4):998-1000. doi: 10.1016/j.jaad.2019.10.003. Epub 2019 Oct 8.
•   Annunziata MC, Ferrillo M, Cinelli E, Panariello L, Rocco D, Fabbrocini G
  Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer. Open Access Maced J Med Sci. 2019 Mar 27;7(6):973-977. doi: 10.3889/oamjms.2019.170. eCollection 2019 Mar 30.
•   Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, Cazzaniga ME, Altomare G
  Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol. 2010 Oct;5(10):1662-3. doi: 10.1097/JTO.0b013e3181ec1729.
•   Bolognia, Jean
  , Jorizzo, Joseph L.Schaffer, Julie V., eds. Dermatology. [Philadelphia] :: Elsevier Saunders, 2012. Print.
•   Chiang HC, Anadkat MJ
  Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions. J Am Acad Dermatol. 2013 Oct;69(4):657-8. doi: 10.1016/j.jaad.2013.05.032.
•   Costello CM, Hill HE, Brumfiel CM, Yang YW, Swanson DL
  Choosing between isotretinoin and acitretin for epidermal growth factor receptor inhibitor and small molecule tyrosine kinase inhibitor acneiform eruptions. J Am Acad Dermatol. 2021 Mar;84(3):840-841. doi: 10.1016/j.jaad.2020.09.090. Epub 2020 Oct 8.
•   Cury-Martins J, Eris APM, Abdalla CMZ, Silva GB, Moura VPT, Sanches JA
  Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol. 2020 Mar - Apr;95(2):221-237. doi: 10.1016/j.abd.2020.01.001. Epub 2020 Feb 15. Review.
•   DeWitt CA, Siroy AE, Stone SP
  Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 2007 Mar;56(3):500-5. Epub 2006 Dec 12.
•   Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J
  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
•   Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M
  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Apr;15(4):504-535.
•   Finlay AY, Khan GK
  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.
•   Gerber PA, Meller S, Eames T, Buhren BA, Schrumpf H, Hetzer S, Ehmann LM, Budach W, Bölke E, Matuschek C, Wollenberg A, Homey B
  Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res. 2012 Feb 23;17:4. doi: 10.1186/2047-783X-17-4.
•   Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Viganò MG, Serafico A, Villa E
  Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. J Oncol. 2009;2009:849051. doi: 10.1155/2009/849051. Epub 2009 Jun 22.
•   Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J
  Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol. 2005 Oct;153(4):849-51.
•   Hirsh V
  Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011 Jun;18(3):126-38.
•   Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group
  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1. Review.
•   Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fernández-Peñas P, Santini D, Jahn F, Jordan K; ESMO Guidelines Committee
  Electronic address: clinicalguidelines@esmo.org. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines(?). Ann Oncol. 2021 Feb;32(2):157-170. doi: 10.1016/j.annonc.2020.11.005. Epub 2020 Nov 25.
•   Lacouture ME
  Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006 Oct;6(10):803-12. Review.
•   Landis MN
  Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and Outcomes. Am J Clin Dermatol. 2020 Jun;21(3):411-419. doi: 10.1007/s40257-020-00508-0. Review.
•   Lewis V, Finlay AY
  10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004 Mar;9(2):169-80. Review.
•   Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K
  Management of egfr tki-induced dermatologic adverse events. Curr Oncol. 2015 Apr;22(2):123-32. doi: 10.3747/co.22.2430. Review.
•   Melosky B
  Supportive care treatments for toxicities of anti-egfr and other targeted agents. Curr Oncol. 2012 Jun;19(Suppl 1):S59-63. doi: 10.3747/co.19.1054.
•   O'Connell NS, Dai L, Jiang Y, Speiser JL, Ward R, Wei W, Carroll R, Gebregziabher M
  Methods for Analysis of Pre-Post Data in Clinical Research: A Comparison of Five Common Methods. J Biom Biostat. 2017 Feb 24;8(1):1-8. doi: 10.4172/2155-6180.1000334.
•   Sc O'brien, Jb Lewis & Wj Cunliffe (1998) The Leeds revised acne grading system, Journal of Dermatological Treatment, 9:4, 215-220, DOI: 10
  3109/09546639809160698
•   Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC
  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007 Dec 1;25(34):5390-6.
•   Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA
  Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003 Oct 8;1:53.
•   Vezzoli P, Marzano AV, Onida F, Alessi E, Galassi B, Tomirotti M, Berti E
  Cetuximab-induced acneiform eruption and the response to isotretinoin. Acta Derm Venereol. 2008;88(1):84-6. doi: 10.2340/00015555-0330.
•   Vickers AJ, Altman DG
  Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ. 2001 Nov 10;323(7321):1123-4. Review.
•   Wolverton, S
  , 2020. Comprehensive Dermatologic Drug Therapy. 4th ed. Elsevier, pp.Chapters 9, 22. In.

A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors

Details for clinical trial NCT04864717